BioLineRx (BLRX) Accounts Payables (2012 - 2025)

BioLineRx's Accounts Payables history runs 14 years deep, the most recent figure standing at $3.5 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 37.44% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (down 37.44% YoY), while the FY2025 annual figure was $3.5 million, down 37.44% from the prior year.
• Accounts Payables was $3.5 million for Q4 2025 at BioLineRx, down from $3.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.9 million in Q4 2023 to a low of $3.5 million in Q2 2025.
• Historically, Accounts Payables has averaged $6.1 million across 5 years, with a median of $5.8 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 56.03% in 2023, then slumped 48.63% in 2024.
• A 5-year view of Accounts Payables shows it stood at $5.6 million in 2021, then increased by 25.13% to $7.0 million in 2022, then jumped by 56.03% to $10.9 million in 2023, then slumped by 48.63% to $5.6 million in 2024, then sank by 37.44% to $3.5 million in 2025.
• The last three Accounts Payables figures came in at $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $3.5 million (Q2 2025), per Business Quant data.